Thomas C. Wehler
Giessen, HE 35392, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 38 publications
Psycho-Emotional Profile and Disease Burden in Wild-Type Transthyretin Amyloidosis.
Journal: Journal of clinical medicine
Published: July 16, 2026
Consolidative Thoracic Radiotherapy With Atezolizumab Maintenance in Extensive-Stage Small Cell Lung Cancer: The Phase 2 TREASURE Randomized Clinical Trial (AIO-TRK-0320).
Journal: JAMA oncology
Published: July 09, 2026
Treatment outcome of NSCLC patients with BRAFnon-V600E mutations: a retrospective, multicentre analysis within the national Network Genomic Medicine (nNGM) Lung Cancer in Germany.
Journal: ESMO open
Published: January 08, 2025
Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 Study.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 10, 2024
Incremental prognostic utility of congestion markers in cardiac transthyretin amyloidosis.
Journal: Clinical research in cardiology : official journal of the German Cardiac Society
Published: June 05, 2024
Corrigendum to "International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancer": [Annals of Oncology 33 (2022) 57-66].
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: January 28, 2022
Nintedanib plus docetaxel after progression on first-line immunochemotherapy in patients with lung adenocarcinoma: Cohort C of the non-interventional study, VARGADO.
Journal: Translational lung cancer research
Published: December 23, 2021
International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancer.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: June 14, 2021
Quality of life in lung cancer survivors treated with tyrosine-kinase inhibitors (TKI): results from the multi-centre cross-sectional German study LARIS.
Journal: Journal of cancer research and clinical oncology
Published: June 02, 2021
Real-World Efficacy of Nintedanib Plus Docetaxel After Progression on Immune Checkpoint Inhibitors: Results From the Ongoing, Non-interventional VARGADO Study.
Journal: Clinical oncology (Royal College of Radiologists (Great Britain))
Published: May 13, 2021
KRAS G12C-mutated advanced non-small cell lung cancer: A real-world cohort from the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315).
Journal: Lung cancer (Amsterdam, Netherlands)
Published: November 05, 2020
A Randomized Phase II Trial Comparing the Efficacy and Safety of Pioglitazone, Clarithromycin and Metronomic Low-Dose Chemotherapy with Single-Agent Nivolumab Therapy in Patients with Advanced Non-small Cell Lung Cancer Treated in Second or Further Line (ModuLung).
Journal: Frontiers in pharmacology
Published: September 24, 2020
Last Updated: 09/26/2026